Therapeutic Asset Ratings

637 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Abemaciclib breast cancer	Fudan University	P4	B (61)
Everolimus breast neoplasm	Fudan University	P4	B (61)
rc48-adc breast cancer	Fudan University	P4	B (61)
Carboplatin breast tumor luminal A or B	Fudan University	P3	B (61)
ETOPOSIDE breast cancer	Fudan University	P3	B (61)
Sorafenib nonpapillary renal cell carcinoma	Fudan University	P3	B (61)
Thalidomide chemotherapy-induced toxicity	Fudan University	P3	B (61)
(+)-VINCRISTINE Pancreatic Cancer	Fudan University	P2	B (61)
PEG LOXENATIDE atypical endometrial hyperplasia	Fudan University	P2/3	B (61)
PEG LOXENATIDE infertility disorder	Fudan University	P2/3	B (61)
Bxcl501 colorectal cancer	Fudan University	P4	B (60)
Adebrelimab GLUT3	Fudan University	P3	B (60)
Adebrelimab scurvy	Fudan University	P3	B (60)
Benmelstobart triple-negative breast carcinoma	Fudan University	P3	B (60)
Calcium folinate pentahydrate GLUT3	Fudan University	P3	B (60)
Calcium folinate pentahydrate Vitamin C	Fudan University	P3	B (60)
Capecitabine Adjuvant Drug Therapy	Fudan University	P3	B (60)
Capecitabine Liver Metastases	Fudan University	P3	B (60)
Carboplatin GLUT3	Fudan University	P3	B (60)
Carboplatin Vitamin C	Fudan University	P3	B (60)
Cetuximab Liver Metastases	Fudan University	P3	B (60)
dl-3-butylphthalide vascular dementia	Fudan University	P3	B (60)
Eloxatin Adjuvant Drug Therapy	Fudan University	P3	B (60)
Eloxatin GLUT3	Fudan University	P3	B (60)
Eloxatin Vitamin C	Fudan University	P3	B (60)

Showing 76 to 100 of 637 assets